Fast Melt Tablet Market
Fast Melt Tablet Market Study by Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensive, NSAIDS, Anti-Allergen Drugs, and Others From 2024 to 2034
Analysis of Fast Melt Tablet Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Fast Melt Tablet Market Outlook (2024 to 2034)
The global fast melt tablet market is estimated to reach a valuation of US$ 16.9 billion in 2024 and further expand at a CAGR of 8.1% to achieve a size of US$ 36.68 billion by 2034-end.
Fast melting tablets are a form of medicine that dissolves in the mouth without chewing. In today's world, it's common to live a hectic lifestyle, due to this the demand for fast melt tablets is increasing among working-class people who don't have access to water all the time. Young people, the elderly, and those who are ill and bedridden are a few of the other class of segments that desire such tablets.
These tablets are easy to manufacture, thus allowing manufacturers to complete the operations and fulfill consumer demand. Key players in the market are actively seeking out government contacts to get the required legal licenses and approval, which is hindering market growth.
The rising need for affordable goods and patient cooperation to improve the quality of life for patients is also playing a crucial role in increasing sales of such tablets. When utilizing oral solid traditional formulations, there is a risk of suffocation or choking. To avoid these risks, doctors in several cases recommend these fast melt tablets to prevent any further medical complications.
To remain afloat in the market, some key companies are constantly putting efforts into implementing different development tactics. Among the growth methods used by these major firms to prosper in the cutthroat industry are product launches, innovations, mergers and acquisitions, partnerships, and extensive research & development. To provide businesses with the most effective and economical solutions, the major market participants are also continuously committed to research and development.
| Report Attribute | Detail |
|---|---|
| Fast Melt Tablet Market Size (2024E) | US$ 16.9 Billion |
| Forecasted Market Value (2034F) | US$ 36.68 Billion |
| Global Market Growth Rate (2024 to 2034) | 8.1% CAGR |
| East Asia Market Growth Rate (2024 to 2034) | 9% |
| North America Market Value (2034F) | US$ 14.24 Billion |
| NSAIDS Segment Growth Rate (2024 to 2034) | 6% CAGR |
| Retail Pharmacies Segment Value (2034F) | US$ 13.56 Billion |
| Key Companies Profiled | Teva Pharmaceutical Industries Ltd.; Novartis AG; AstraZeneca; Mylan N.V.; Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co., Inc.; Bausch Health; GlaxoSmithKline Plc; Sun Pharmaceutical Industries Ltd.; Bayer AG; Eli Lily and Company; Dr. Reddy’s Laboratories Ltd.; Takeda Pharmaceutical Company Limited; Kissei Pharmaceutical Co. Ltd. |
Demand for fast melt tablets was analyzed to observe stable recovery in the short-term, with a positive growth position in the long run. High adoption of fast melt tablet technology is projected to offer lucrative opportunities in the near future.
What are the major drivers of the Fast Melt Tablet Market?
Fast melts tablet is an oral solid dosage form that disintegrates in the oral cavity without water or chewing. Fast or mouth-dissolving tablets have been formulated for active patients who are busy traveling, and do not have access to water, or a patient who is unable to swallow. It is highly adopted by pediatric, geriatric, and bedridden patients.
Because of constant innovations in the field of oral-dissolving drug delivery systems, they are now used for several benefits, such as quick drug therapy intervention, increased bioavailability, good stability, easy manufacturing, united and accurate dosing, easy handling, motion sickness, suede episodes of allergic attack or coughing, where an ultra-rapid onset of action required.
The increase in the elderly population, who are unable to swallow the medicine, and the rise in product promotion aimed at raising awareness of the treatment of patients are creating opportunities, as stated in the fast melt tablet industry analysis. Rise in demand for patient compliance and cost-effective products to improve the quality of patients’ lives.
Due to the administration of oral solid traditional formulations, there is a risk of choking or suffocation. In addition, technological innovations in fast melt tablets meet pharmacopeia requirements where the tablet disperses rapidly before swallowing and disintegrates in less than 3 minutes. This is supporting the market growth.
High Adoption of Fast Melt Tablets Expected to Boost the Demand
High adoption of fast-melt tablets by the geriatric population gives demand progress for the market during the forecast period. First-pass metabolism is a big issue in a conventional oral formulation that is possibly prevented with the help of these tablets, according to the fast melt tablet industry outlook.
These drug delivery systems are capable of achieving patient compliance to a great extent, which boosts the demand. Self-administration is possible with high bioavailability immediate action and decreased side effects of the drug to patients. This is the formulation driving force for more adoption.
However, some technological challenges that create hindrances in this drug delivery system are overcome with extensive research in formulation and development. This adds to the adoption of fast dissolving tablets.
North America Fast Melt Tablet Industry Outlook
Due to the market player innovation, the North American market occupies an essential part of the global demand. The primary factor that makes the North American market the key revenue-generating region in this field is the presence of major companies manufacturing advanced drug delivery systems that are funding several R&D activities for the market.
Along with the above-mentioned factors, the increased disposable income and developments in the healthcare industry are other key factors leading to market position, as per the fast melt tablet industry analysis.
Europe Fast Melt Tablets Demand Outlook
Europe is the second leading region in this field due to the high percentage of geriatric population. According to the research done by Eurostat in 2019, there were 90.4 million older people. The geriatric population is adopting due to swallowing issues, and the gastrointestinal tract is also weak for old age patients, so they adopt faster melt tablets.
In addition, a rising incidence of heart attacks in Europe, so in such cases, fast melt tablets act for quick delivery and immediate action. These are some factors that are driving the fast melt tablet market.
Who are the key players in the Fast Melt Tablet Market?
Some of the manufacturers of fast melt tablets are :
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- AstraZeneca
- Mylan N.V.
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bausch Health
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd.
- Bayer AG
- Eli Lily and Company
- Dr. Reddy’s Laboratories Ltd.
- Takeda Pharmaceutical Company Limited
- Kissei Pharmaceutical Co. Ltd.
For instance, in June 2019, Kissei Pharmaceutical Co., Ltd. launched GLUBES, which is the new orally disintegrating dosage form of GLUBES Combination Tab.
Fast Melt Tablet Market Report Highlights :
- Shifting Industry dynamics
- In-depth market segmentation
- Historical, current, and projected industry size and recent industry trends
- Key Competition landscape
- Strategies for key players and product offerings
- Potential and niche segments/regions exhibiting promising growth
- A neutral perspective towards market performance
Segmentation of Fast Melt Tablet Market Research
-
By Drug Class :
- Anti-Psychotics
- Anti-Epileptics
- CNS Stimulants
- Anxiolytics
- Anti-Parkinsonian Drugs
- Anti-Hypertensive
- NSAIDS
- Anti-Allergy Drugs
- Proton Pump Inhibitors
- Others
-
By Indication :
- CNS Diseases
- GI Diseases
- CVS Disorders
- Allergy Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis and Forecast
- 6.1. Drug Class
- 6.2. Indication
- 6.3. Distribution Channel
- 7. Global Market Analysis and Forecast, By Drug Class
- 7.1. Anti-Psychotics
- 7.2. Anti-Epileptics
- 7.3. CNS Stimulants
- 7.4. Anxiolytics
- 7.5. Anti-Parkinsonian Drugs
- 7.6. Anti-Hypertensive
- 7.7. NSAIDS
- 7.8. Anti-Allergy Drugs
- 7.9. Proton Pump Inhibitors
- 7.10. Others
- 8. Global Market Analysis and Forecast, By Indication
- 8.1. CNS Diseases
- 8.2. GI Diseases
- 8.3. CVS Disorders
- 8.4. Allergy
- 8.5. Others
- 9. Global Market Analysis and Forecast, By Distribution Channel
- 9.1. Hospital Pharmacies
- 9.2. Retail Pharmacies
- 9.3. Drug Stores
- 9.4. Online Pharmacies
- 10. Global Market Analysis and Forecast, By Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. East Asia
- 10.6. South Asia & Pacific
- 10.7. MEA
- 11. North America Sales Analysis and Forecast, by Key Segments and Countries
- 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries
- 13. Western Europe Sales Analysis and Forecast, by Key Segments and Countries
- 14. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries
- 15. East Asia Sales Analysis and Forecast, by Key Segments and Countries
- 16. South Asia & Pacific Sales Analysis and Forecast, by Key Segments and Countries
- 17. MEA Sales Analysis and Forecast, by Key Segments and Countries
- 18. Sales Forecast by Drug Class, Indication, and Distribution Channel for 30 Countries
- 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 20. Company Profile
- 20.1. Teva Pharmaceutical Industries Ltd.
- 20.2. Novartis AG
- 20.3. AstraZeneca
- 20.4. Mylan N.V.
- 20.5. Pfizer Inc.
- 20.6. Johnson & Johnson Services Inc.
- 20.7. F. Hoffmann-La Roche Ltd.
- 20.8. Merck & Co., Inc.
- 20.9. Bausch Health
- 20.10. GlaxoSmithKline plc
- 20.11. Sun Pharmaceutical Industries Ltd.
- 20.12. Bayer AG
- 20.13. Eli Lily and Company
- 20.14. Dr. Reddy’s Laboratories Ltd.
- 20.15. Takeda Pharmaceutical Company Limited
- 20.16. Kissei Pharmaceutical Co.Ltd.
List Of Table
Table 01: Global Market US$ Mn Forecast by Region
Table 02: Global Market US$ Mn Forecast by Drug Class
Table 03: Global Market US$ Mn Forecast by Indication
Table 04: Global Market US$ Mn Forecast by Distribution Channel
Table 05: North America Market US$ Mn Forecast by Country
Table 06: North America Market US$ Mn Forecast by Drug Class
Table 07: North America Market US$ Mn Forecast by Indication
Table 08: North America Market US$ Mn Forecast by Distribution Channel
Table 09: Latin America Market US$ Mn Forecast by Country
Table 10: Latin America Market US$ Mn Forecast by Drug Class
Table 11: Latin America Market US$ Mn Forecast by Indication
Table 12: Latin America Market US$ Mn Forecast by Distribution Channel
Table 13: Western Europe Market US$ Mn Forecast by Country
Table 14: Western Europe Market US$ Mn Forecast by Drug Class
Table 15: Western Europe Market US$ Mn Forecast by Indication
Table 16: Western Europe Market US$ Mn Forecast by Distribution Channel
Table 17: Eastern Europe Market US$ Mn Forecast by Country
Table 18: Eastern Europe Market US$ Mn Forecast by Drug Class
Table 19: Eastern Europe Market US$ Mn Forecast by Indication
Table 20: Eastern Europe Market US$ Mn Forecast by Distribution Channel
Table 21: East Asia Market US$ Mn Forecast by Country
Table 22: East Asia Market US$ Mn Forecast by Drug Class
Table 23: East Asia Market US$ Mn Forecast by Indication
Table 24: East Asia Market US$ Mn Forecast by Distribution Channel
Table 25: South Asia & Pacific Market US$ Mn Forecast by Country
Table 26: South Asia & Pacific Market US$ Mn Forecast by Drug Class
Table 27: South Asia & Pacific Market US$ Mn Forecast by Indication
Table 28: South Asia & Pacific Market US$ Mn Forecast by Distribution Channel
Table 29: MEA Market US$ Mn Forecast by Country
Table 30: MEA Market US$ Mn Forecast by Drug Class
Table 31: MEA Market US$ Mn Forecast by Indication
Table 32: MEA Market US$ Mn Forecast by Distribution Channel
List Of Figures
Figure 01: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Class
Figure 02: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 03: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 04: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Region
Figure 05: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Class
Figure 06: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 07: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 08: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 09: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Class
Figure 10: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 11: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 12: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 13: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Class
Figure 14: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 15: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 16: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 17: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Class
Figure 18: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 19: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 20: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 21: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Class
Figure 22: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 23: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 24: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 25: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Class
Figure 26: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 27: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 28: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 29: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Drug Class
Figure 30: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Indication
Figure 31: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distribution Channel
Figure 32: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
- FAQs -
What is the growth outlook for the fast-melt tablet market by 2034?
According to Fact.MR, the fast melt tablet market is evaluated to rise at 8.1% CAGR during the forecast period.
What factors are driving the global market growth?
Inability to swallow tablets by patients, increased bioavailability, and adoption by pediatric patients are driving the market growth.
Which region is analyzed to lead in the fast melt tablet market by 2034?
North America is analyzed to lead in the global market for fast melt tablets in terms of revenue generation during the forecast period.
Fast Melt Tablet Market